We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+14.09%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$79.1B
AUM Growth
+$7.99B
(+11%)
Cap. Flow
-$5.86B
Cap. Flow
% of AUM
-7.4%
Top 10 Holdings %
Top 10 Hldgs %
22.63%
Holding
2,061
New
445
Increased
504
Reduced
465
Closed
231
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sysco
SYY
|
+$273M |
| 2 |
Waste Management
WM
|
+$168M |
| 3 |
Lowe's Companies
LOW
|
+$160M |
| 4 |
PNC Financial Services
PNC
|
+$154M |
| 5 |
Unilever
UL
|
+$122M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$548M |
| 2 |
Apple
AAPL
|
+$372M |
| 3 |
CSX Corp
CSX
|
+$369M |
| 4 |
Infosys
INFY
|
+$238M |
| 5 |
Kimberly-Clark
KMB
|
+$235M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.16% |
| 2 | Healthcare | 14.65% |
| 3 | Financials | 13.08% |
| 4 | Industrials | 9.66% |
| 5 | Consumer Discretionary | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
iShares Core S&P Small-Cap ETF
IJR
$111B
| $38.6M | 0.05% |
420,241
+2,212
| +0.5% | +$182K |
|
252
Malibu Boats
MBUU
$562M
| $38M | 0.05% |
609,329
+37,302
| +7% | +$2.15M |
|
|
TWN
253
Taiwan Fund
TWN
$518M
| $37.9M | 0.05% |
1,477,233
-4,673
| -0.3% | -$120K |
|
|
CTLT
254
DELISTED
CATALENT, INC.
CTLT
| $37.8M | 0.05% |
362,806
-15,103
| -4% | -$1.46M |
|
255
iShares Core S&P Mid-Cap ETF
IJH
$125B
| $37.8M | 0.05% |
821,310
+41,585
| +5% | +$1.75M |
|
256
Ciena
CIEN
$57.2B
| $37.7M | 0.05% |
713,377
+64,978
| +10% | +$2.89M |
|
257
United Therapeutics
UTHR
$22.6B
| $37.3M | 0.05% |
245,791
+30,955
| +14% | +$4.06M |
|
258
iShares MSCI EAFE ETF
EFA
$79.4B
| $37.2M | 0.05% |
509,873
+233,834
| +85% | +$16M |
|
259
West Pharmaceutical
WST
$24.5B
| $36.9M | 0.05% |
130,203
+3,453
| +3% | +$969K |
|
260
Lennox International
LII
$15.1B
| $36.4M | 0.05% |
132,894
+127,144
| +2,211% | +$36.2M |
|
261
MDU Resources
MDU
$4.34B
| $36.2M | 0.05% |
3,612,833
+244,624
| +7% | +$2.29M |
|
262
iShares National Muni Bond ETF
MUB
$45.3B
| – | – |
0
| – | – |
|
263
Diageo
DEO
$51.6B
| $35.7M | 0.05% |
224,558
+3,343
| +2% | +$499K |
|
264
Adaptive Biotechnologies
ADPT
$3.75B
| $33.9M | 0.04% |
572,793
-173,453
| -23% | -$8.94M |
|
265
Clorox
CLX
$12.8B
| $33.7M | 0.04% |
166,824
-179,462
| -52% | -$37.1M |
|
|
KF
266
Korea Fund
KF
$244M
| $33.6M | 0.04% |
831,964
+3,317
| +0.4% | +$115K |
|
|
JOF
267
Japan Smaller Capitalization Fund
JOF
$348M
| $32.9M | 0.04% |
3,636,765
| – | – |
|
268
Viatris
VTRS
$19B
| $32.6M | 0.04% |
+1,740,424
| New | +$28.4M |
|
|
SWI
269
DELISTED
SolarWinds Corporation Common Stock
SWI
| $32.1M | 0.04% |
2,034,330
-242,604
| -11% | -$5.31M |
|
270
Cardinal Health
CAH
$55.7B
| $32M | 0.04% |
597,889
+214,357
| +56% | +$11.1M |
|
271
Align Technology
ALGN
$12.1B
| $31.9M | 0.04% |
59,684
+10,753
| +22% | +$4.83M |
|
272
LCI Industries
LCII
$2.57B
| $31.8M | 0.04% |
244,943
+14,506
| +6% | +$1.78M |
|
273
Emergent Biosolutions
EBS
$274M
| $31.3M | 0.04% |
349,324
+15,206
| +5% | +$1.4M |
|
274
Vertex Pharmaceuticals
VRTX
$123B
| $31.2M | 0.04% |
132,109
-74,073
| -36% | -$17M |
|
275
Agilent Technologies
A
$39.9B
| $31.1M | 0.04% |
262,233
+127,111
| +94% | +$14.1M |
|
Similar funds
QCM
Lazard Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Lazard Asset Management held 2,061 positions worth $79.1B, up 11% from $71.1B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Lazard Asset Management withdrew a net $5.86B in Q4 2020, closing 231 positions and reducing 465 holdings. Its most notable exit was Unilever NV New York Registry Shares, an estimated $112M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lazard Asset Management opened a new position in Sotera Health worth $100M.
- Lazard Asset Management's largest Q4 2020 buy was Sotera Health: 3,651,831 shares worth $100M.
- Lazard Asset Management added most to Sysco in Q4 2020, an estimated $273M increase.
- Lazard Asset Management's biggest Q4 2020 reduction was Pfizer, cutting an estimated $548M.
- Lazard Asset Management fully exited Unilever NV New York Registry Shares in Q4 2020, selling an estimated $112M.
- Lazard Asset Management's ten largest holdings make up 23% of its $79.1B portfolio in Q4 2020.
- Lazard Asset Management opened 445 new positions and closed 231 in Q4 2020.
- Lazard Asset Management's portfolio value rose 11% quarter-over-quarter to $79.1B.
Based on Lazard Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.